Home>>Signaling Pathways>> Proteases>> ACE>>Cilazapril

Cilazapril (Synonyms: Ro 31-2848)

Catalog No.GC12859

ACE inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

Cilazapril Chemical Structure

Cas No.: 88768-40-5

Size Price Stock Qty
1mg
$34.00
In stock
5mg
$84.00
In stock
10mg
$134.00
In stock
25mg
$294.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Cilazapril is an inhibitor of angiotensin converting enzyme (ACE) with IC50 value of 1.93nM [1].

Cilazapril is a monoethyl prodrug of cilazaprilat. The latter shows an IC50 value of 1.93nM to rabbit lung ACE when using Hip-His-Leu substrate in vitro. Cilazaprilat is most potent among all the ACE inhibitors when the ACE is from rabbit lung, human plasma, hog kidney or human lung. Cilazaprilat is specific. It shows no inhibition to a variety of lipolytic and proteolytic enzymes even the concentration of it is up to more than 10000 fold higher than its IC50 value. Cilazapril and cilazaprilat also show inhibition of the angiotensin I (AI) pressor response with ED50 vallues of 0.44 and 0.06 mmol/kg. In addition, when cilazapril is treated as an antihypertensive drug, the maximum decrease in blood pressure relative to the control is 110mmHg on day 21 [1].

References:
[1] Waterfall JF. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. Br J Clin Pharmacol. 1989;27

Reviews

Review for Cilazapril

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Cilazapril

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.